(Q33503243)

27 July 2017

title

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study (English)

1 reference

27 July 2017

Frasci G

1

1 reference

27 July 2017

Comella P

2

1 reference

27 July 2017

D'Aiuto G

3

1 reference

27 July 2017

Budillon A

4

1 reference

27 July 2017

Barbarulo D

5

1 reference

27 July 2017

Thomas R

6

1 reference

27 July 2017

Capasso I

7

1 reference

27 July 2017

Casaretti R

8

1 reference

27 July 2017

Daponte A

9

1 reference

27 July 2017

Caponigro F

10

1 reference

27 July 2017

Gravina A

11

1 reference

27 July 2017

Maiorino L

12

1 reference

27 July 2017

Caratení G

13

1 reference

27 July 2017

Gentile A

14

1 reference

27 July 2017

Comella G

15

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 May 1998

1 reference

Breast Cancer Research and Treatment

27 July 2017

published in

1 reference

27 July 2017

volume

49

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

13-26

1 reference

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Cisplatin as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Cisplatin and its analogues in the treatment of advanced breast cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

7 January 2021

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

7 January 2021

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

7 January 2021

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

7 January 2021

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005945218155

7 January 2021

Identifiers

DOI

10.1023/A:1005945218155

1 reference

Dimensions Publication ID

27 July 2017

1000296345

0 references

1 reference